Skip to main content
OpenTrials
Completed

NCT Number: NCT01137110

Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Subarachnoid Hemorrhage Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Barnes-jewish Hospital

St Louis, Missouri, 63110, United States

About this study

This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years of age
  • Diagnosis of spontaneous SAH

Exclusion criteria

  • SAH secondary to trauma or arteriovenous malformation
  • Early death (defined as death within 3 days of presentation)
  • Known allergy to levetiracetam
  • Know seizure history on chronic AEDs
  • Pregnancy
  • Current incarceration

Treatment and study plan

Brief LEV

Other

Levetiracetam 1000mg BID x 3 days for prophylaxis

Extended LEV

Other

Levetiracetam 1000mg BID for length of hospital stay for prophylaxis

Primary outcomes

  1. In-hospital Seizures

    Time frame: from hospital admission to hospital discharge

    from admission to In-hospital seizures after aSAH

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage

Acronym: DOPAST

Important dates

Study start
2010
Primary completion
2013
Study completion
2017
First posted
Jun 4, 2010
Registry last updated
Jul 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.